Feed ELOX
EL

Eloxx Pharmaceuticals, Inc.

ELOX · NASDAQ

$17.45 -8.06% (-$1.53)
1M -2.72%
Market Cap $314.0
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
3/9
Valuation
-
N/A
P/E N/A
PEG N/A
EV/EBITDA N/A
Growth
-
N/A
EPS growth N/A
Book val. growth N/A
Rev. growth N/A
Profitability
-
N/A
Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
0 /100
Poor
ROIC 1,263.55%
Asset turnover 0.00x
ROA 170.74%
Debt
56 /100
Moderate
Current ratio 0.87x
Net debt/EBITDA 0.18x
Int. coverage -16.64x
Stability
44 /100
Moderate
Beta -9.95x
Profitable years 0
EPS volatility 34.31%

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre ELOX
Online

Despre companie

Eloxx Pharmaceuticals, Inc. (ELOX) is a biotechnology company specializing in the development of therapeutic therapies for genetic diseases and rare conditions. The company focuses on developing drug products that can correct genetic mutations and provide treatment for patients suffering from genetic disorders. Eloxx Pharmaceuticals targets the treatment of rare diseases such as cystic fibrosis, Duchenne muscular dystrophy, and other genetic disorders. With the growing awareness of the need for genetic disease treatment, Eloxx Pharmaceuticals, Inc. has the potential for sustained growth. Eloxx Pharmaceuticals, Inc. (ELOX) shares might be an interesting choice for investors seeking involvement in the biotechnology and therapeutic therapies for genetic diseases.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Sumit Aggarwal

Employees

10

Headquarters

Watertown

Evenimente viitoare

11 NOV.

Earnings

Upcoming earnings report

53d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.